Skip to main content
Canna~Fangled Abstracts

Endocannabinoid and dopaminergic system: the pas de deux underlying human motivation and behaviors

By March 12, 2021March 22nd, 2021No Comments
Endocannabinoid system (ECS) has been identified ever since cannabinoid, an active substance of Cannabis, was known to interact with endogenous cannabinoid (endocannabinoid/eCB) receptors.
Review

doi: 10.1007/s00702-021-02326-y. Online ahead of print.

Affiliations 

Abstract

Endocannabinoid system (ECS) has been identified ever since cannabinoid, an active substance of Cannabis, was known to interact with endogenous cannabinoid (endocannabinoid/eCB) receptors. It later turned out that eCB was more intricate than previously thought. It has a pervasive role and exerts a multitude of cellular signaling mechanisms, regulating various physiological neurotransmission pathways in the human brain, including the dopaminergic (DA) system. eCB roles toward DA system were robust, clearly delineated, and reproducible with respect to physiological as well as pathological neurochemical and neurobehavioral manifestations of DA system, particularly those involving the nigrostriatal and mesocorticolimbic pathways. The eCB-DA system regulates the basics in the Maslow’s pyramid of hierarchy of needs required for individual survival such as food and sexual activity for reproductive purpose to those of higher needs in the pyramid, including self-actualization behaviors leading to achievement and reward (e.g., academic- and/or work-related performance and achievements). It is, thus, interesting to specifically discuss the eCB-DA system, not only on the molecular level, but also its tremendous potential to be developed as a future therapeutic strategy for various neuropsychiatric problems, including obesity, drug addiction and withdrawal, pathological hypersexuality, or low motivation behaviors.

 

Keywords: Clinical implications, Dopaminergic system, Endocannabinoid system, Molecular mechanisms, Neurobehavior

Similar articles

References

    1. Adermark L, Lovinger DM (2007) Retrograde endocannabinoid signaling at striatal synapses requires a regulated postsynaptic release step. Proc Natl Acad Sci USA 104:20564–20569. https://doi.org/10.1073/pnas.0706873104 – DOI – PubMed
    1. Adermark L, Talani G, Lovinger DM (2009) Endocannabinoid-dependent plasticity at GABAergic and glutamatergic synapses in the striatum is regulated by synaptic activity. Eur J Neurosci 29:32–41. https://doi.org/10.1111/j.1460-9568.2008.06551.x – DOI – PubMed – PMC
    1. Altun A, Yildirim K, Ozdemir E, Bagcivan I, Gursoy S, Durmus N (2015) Attenuation of morphine antinociceptive tolerance by cannabinoid CB1 and CB2 receptor antagonists. J Physiol Sci 65:407–415. https://doi.org/10.1007/s12576-015-0379-2 – DOI – PubMed
    1. Baker PM, Jhou T, Li B, Matsumoto M, Mizumori SJ, Stephenson-Jones M, Vicentic A (2016) The lateral habenula circuitry: reward processing and cognitive control. J Neurosci 36:11482–11488. https://doi.org/10.1523/JNEUROSCI.2350-16.2016 – DOI – PubMed – PMC
    1. Batalla A, Janssen H, Gangadin SS, Bossong MG (2019) The potential of cannabidiol as a treatment for psychosis and addiction: who benefits most? A systematic review. J Clin Med. https://doi.org/10.3390/jcm8071058 – DOI – PubMed – PMC

Publication types

LinkOut – more resources


Leave a Reply